What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Surgery, Oncology, Bevacizumab and Chemotherapy.
His Internal medicine research includes themes of Gastroenterology and Glioma.
In his research on the topic of Surgery, Interim analysis, Hydroxycarbamide, Imatinib mesylate and Imatinib is strongly related with Tyrosine-kinase inhibitor.
His work carried out in the field of Oncology brings together such families of science as Astrocytoma, Retrospective cohort study, Epidermal growth factor receptor and Pharmacology.
The various areas that James J. Vredenburgh examines in his Bevacizumab study include Vascular endothelial growth factor and Survival analysis.
His Chemotherapy research is multidisciplinary, incorporating elements of Breast cancer, Tolerability and Gefitinib.
His most cited work include:
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma (1837 citations)
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (1184 citations)
- Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma (938 citations)
What are the main themes of his work throughout his whole career to date?
James J. Vredenburgh spends much of his time researching Internal medicine, Oncology, Surgery, Chemotherapy and Bevacizumab.
His work deals with themes such as Gastroenterology and Glioma, which intersect with Internal medicine.
As part of the same scientific family, James J. Vredenburgh usually focuses on Glioma, concentrating on Pathology and intersecting with Cancer research.
His work in Oncology covers topics such as Pharmacology which are related to areas like Erlotinib.
His Chemotherapy study combines topics in areas such as Breast cancer, Metastatic breast cancer and Bone marrow.
His study in Bevacizumab is interdisciplinary in nature, drawing from both Progressive disease, Clinical trial, Vascular endothelial growth factor, Radiosurgery and Glioblastoma.
He most often published in these fields:
- Internal medicine (59.48%)
- Oncology (41.50%)
- Surgery (33.99%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (59.48%)
- Oncology (41.50%)
- Bevacizumab (29.08%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Bevacizumab, Surgery and Temozolomide.
He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Gastroenterology and, in certain cases, Neutropenia.
His studies in Oncology integrate themes in fields like Pharmacokinetics, Adverse effect, Pathology, Recurrent glioblastoma and Glioblastoma.
His Bevacizumab study also includes
- Complication most often made with reference to Radiation therapy,
- Glioma which intersects with area such as Salvage therapy.
In most of his Surgery studies, his work intersects topics such as Clinical trial.
His studies deal with areas such as Progressive disease and Dacarbazine as well as Temozolomide.
Between 2011 and 2021, his most popular works were:
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients (280 citations)
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. (127 citations)
- Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas (122 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
James J. Vredenburgh focuses on Bevacizumab, Internal medicine, Surgery, Oncology and Temozolomide.
His Bevacizumab research includes elements of Perforation, Nuclear medicine, Confidence interval, Effective diffusion coefficient and Radiation therapy.
His work in Phases of clinical research, Clinical endpoint, Neutropenia, Dacarbazine and Chemotherapy is related to Internal medicine.
His Surgery study incorporates themes from Gastroenterology and Glioma.
His Oncology study combines topics from a wide range of disciplines, such as Glioblastoma, Toxicity and Retrospective cohort study.
His research in Temozolomide intersects with topics in Proteasome inhibitor, Proteasome, Angiogenesis, Cell growth and Programmed cell death.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
